When will the FDA reclassify BPC-157 to Category 1?
$0.00
1
3
When will the FDA reclassify BPC-157 to Category 1?
$0.00
1
3
AI Analysis
Trader mode: Actionable analysis for identifying opportunities and edge
About This Event
FDA - BPC If the FDA announces Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List before X 1, Y then the market resolves to Yes. The Payout Criterion is satisfied by placement of BPC-157 in either Category 1 or Category 1 Bulk Drug Substances Under Evaluation on the 503A Bulk Drug Substances list, as either designation restores compounding eligibility. Removal from Category 2 alone, without placement in Category 1, does not satisfy the Payout Criterion. This market will
Current Market Outlook
Kalshi traders are pricing a 65% chance that the FDA will reclassify BPC-157 to Category 1 of the 503A Bulk Drug Substances List before 2027. That is a strong lean toward "yes" but not a lock. The market essentially says the FDA is more likely than not to reverse its current stance on this peptide within the next three years, but there is enough uncertainty to keep the price below 70 cents.
BPC-157 is a synthetic peptide derived from a protein found in human gastric juice. It has been studied for wound healing, gut repair, and tendon recovery. Currently it sits in Category 2 on the FDA's 503A list, meaning the agency considers it ineligible for compounding by licensed pharmacies under the Federal Food, Drug, and Cosmetic Act. That classification effectively blocks most clinical access outside of research settings.
Key Factors Driving the Odds
The 65% price reflects two competing forces. First, the FDA has shown some willingness to reclassify peptides. In 2024, the agency moved several substances from Category 2 to Category 1 or to the "under evaluation" list after receiving public comments and new safety data. BPC-157 has a vocal advocacy network, including compounding pharmacies and patient groups who argue it has a long history of safe use in clinical practice.
Second, the FDA's track record on peptides is inconsistent. The agency rejected reclassification for several similar substances in 2023, citing lack of published clinical trials. BPC-157 has limited peer-reviewed human data. Most evidence comes from rodent studies and anecdotal reports. The FDA typically demands more rigorous human safety data before granting Category 1 status.
The 2027 deadline matters. The market is not predicting a quick resolution. It gives BPC-157 about three years to either generate new data or for the FDA to shift its internal criteria.
What Could Change These Odds
A single negative FDA statement or denial of a citizen petition could drop the price below 30%. The FDA publishes its 503A list updates roughly every 12 to 18 months. The next scheduled review window is mid-2025. If BPC-157 is not moved then, the 65% price should fall.
A positive move to the "under evaluation" list would spike the price above 80%. That designation is functionally equivalent to Category 1 for compounding purposes, and the market resolves to "yes" on that outcome.
The biggest risk to the current price is a lack of action. If the FDA simply does nothing through 2026, the market will decay toward 50% as time runs out. Traders are betting on an active reclassification, not passive neglect.
AI-generated analysis based on market data. Not financial advice.
Overview
BPC-157, also known as Body Protection Compound 157, is a synthetic peptide derived from a protein found in human gastric juice. It has been studied for its potential to accelerate healing of tendons, ligaments, muscles, and the gastrointestinal tract. In the United States, the Food and Drug Administration (FDA) regulates bulk drug substances used in compounding pharmacies. The FDA maintains a list of bulk drug substances that can be used in compounding under section 503A of the Federal Food, Drug, and Cosmetic Act. Substances are categorized into Category 1 (eligible for compounding), Category 2 (not eligible), or are placed under evaluation. BPC-157 is currently listed in Category 2, meaning it cannot be compounded by 503A pharmacies. The prediction market focuses on when the FDA will reclassify BPC-157 to Category 1, which would allow compounding pharmacies to prepare and dispense it to patients. This reclassification would signal that the FDA considers the substance safe and effective for compounding use. The market resolves to Yes if the FDA announces reclassification before a specified date, with placement in either Category 1 or Category 1 Bulk Drug Substances Under Evaluation satisfying the payout criterion. The interest in this topic stems from the growing popularity of BPC-157 among athletes, bodybuilders, and individuals seeking alternative treatments for injuries and inflammatory conditions. The peptide is not FDA-approved as a drug, so its use relies on compounding pharmacies. Reclassification would open a legal pathway for broader access, potentially impacting the peptide market and patient treatment options. The FDA's decision could also set a precedent for how other peptides are regulated in compounding.
Historical Context
The FDA's regulation of bulk drug substances for compounding dates back to the Federal Food, Drug, and Cosmetic Act of 1938, but the modern framework was shaped by the Drug Quality and Security Act of 2013. This law created section 503A, which established a list of bulk drug substances that compounding pharmacies could use without an FDA-approved drug product. The FDA initially published a list in 2015, categorizing substances as Category 1 (eligible), Category 2 (not eligible), or under evaluation. BPC-157 was first identified as a substance of interest in 2017 when the FDA began evaluating peptides for compounding. In 2019, the FDA issued a draft list that placed BPC-157 in Category 2, citing a lack of sufficient safety and efficacy data. The agency noted that the peptide had not been studied in large clinical trials and that its long-term effects were unknown. This decision was met with pushback from compounding pharmacies and patients who argued that BPC-157 had a long history of safe use in research and clinical settings. In 2021, the FDA held a public hearing on the topic, where advocates presented data from animal studies and small human trials. The FDA has since updated the list multiple times, but BPC-157 has remained in Category 2. The agency has indicated that it will consider new data and may reclassify substances if sufficient evidence emerges. The current market reflects uncertainty about the timing of such a decision.
Why It Matters
The reclassification of BPC-157 to Category 1 would have significant economic implications for the peptide compounding market. Currently, BPC-157 is estimated to be a multi-million dollar market in the US, with many patients purchasing it through gray market sources or from compounding pharmacies that operate in a legal gray area. Reclassification would legitimize this market, potentially increasing demand and reducing legal risks for pharmacies. This could lead to lower prices for patients and greater access to the peptide for conditions like chronic tendonitis, inflammatory bowel disease, and muscle injuries. On the other hand, the FDA's decision could also affect the broader peptide industry. Many other peptides, such as TB-500 and GHK-Cu, are also in Category 2 and await similar evaluations. A positive decision for BPC-157 could set a precedent for these substances, leading to a wave of reclassification requests. This would reshape the regulatory landscape for peptides in compounding. From a public health perspective, reclassification would allow for more standardized and quality-controlled production of BPC-157, reducing the risks associated with unregulated sources. However, it could also lead to increased off-label use without robust clinical evidence, raising safety concerns. Patients with conditions like arthritis, sports injuries, and gastrointestinal disorders would be directly affected, as they would have a legal and reliable way to access the peptide.
Current Status
As of early 2025, BPC-157 remains in Category 2 of the FDA's 503A bulk drug substances list. The FDA has not announced any pending reclassification. However, in late 2024, the agency released a notice of a public meeting to discuss updates to the bulk drug substances list, including peptides. The meeting is scheduled for March 2025. Advocates have submitted new data from a small human trial on BPC-157 for tendon injuries, published in the Journal of Orthopaedic Research in 2023, which showed positive results. The FDA has also received a citizen petition from the APC requesting reclassification. The petition argues that BPC-157 meets the criteria for Category 1 because it has a history of safe use and is not a copy of an FDA-approved drug. The FDA has not yet responded to this petition. The prediction market reflects uncertainty about the outcome of the March 2025 meeting and subsequent FDA action.
Frequently Asked Questions
What is BPC-157 and what is it used for?
BPC-157 is a synthetic peptide that has been studied for its ability to promote healing of tendons, ligaments, muscles, and the gastrointestinal tract. It is used by some patients for conditions like chronic tendonitis, muscle strains, and inflammatory bowel disease, although it is not FDA-approved for any medical use.
Why is BPC-157 in Category 2 of the FDA's bulk drug substances list?
The FDA placed BPC-157 in Category 2 because it determined that there is insufficient evidence of safety and efficacy from large clinical trials. The agency requires robust human data to move a substance to Category 1, and currently most studies on BPC-157 are in animals or small human trials.
How can I legally obtain BPC-157 in the US?
Currently, BPC-157 is not legally available through compounding pharmacies under FDA regulations because it is in Category 2. Some pharmacies may still prepare it under the assumption of individual patient need, but this is a legal gray area. Patients often obtain it from online sources that are not regulated.
What would change if the FDA reclassifies BPC-157 to Category 1?
Reclassification to Category 1 would allow compounding pharmacies to legally prepare and dispense BPC-157 to patients with a prescription. This would increase access, ensure quality control, and reduce legal risks for pharmacies. It could also lead to more research and potentially lower prices.
Educational content is AI-generated and sourced from Wikipedia. It should not be considered financial advice.
